Collection of Samples From Pregnant Women for the Evaluation of Preeclampsia (Pre-E) Biomarkers
Status: | Recruiting |
---|---|
Conditions: | High Blood Pressure (Hypertension), Renal Impairment / Chronic Kidney Disease, Women's Studies, Endocrine, Nephrology, Pulmonary, Hematology |
Therapuetic Areas: | Cardiology / Vascular Diseases, Endocrinology, Hematology, Nephrology / Urology, Pulmonary / Respiratory Diseases, Reproductive |
Healthy: | No |
Age Range: | 18 - 45 |
Updated: | 1/27/2019 |
Start Date: | January 2016 |
End Date: | January 2020 |
Contact: | Alanna Menez |
Email: | alanna.menez@progenity.com |
Phone: | 8582605216 |
Preeclampsia (Pre-E) is a hypertensive disease of pregnancy with multi-system involvement
that usually occurs in the second half of pregnancy. Pre-E occurs in 5% to 7% of U.S.
pregnancies, and is the third-leading cause of U.S. maternal death. Improvements to the
current diagnostic paradigm have been evaluated. However, no stand-alone diagnostic method
has emerged that more accurately identifies women at risk for preeclampsia, warranting
improvements in diagnosing Pre-E.
This sample collection study will obtain serum and urine samples from pregnant women who
present with clinical signs, symptoms, or conditions contributing to the suspicion of Pre-E.
Samples will be used to evaluate and validate the performance of an assay intended to aid in
assessing the risk of Pre-E.
that usually occurs in the second half of pregnancy. Pre-E occurs in 5% to 7% of U.S.
pregnancies, and is the third-leading cause of U.S. maternal death. Improvements to the
current diagnostic paradigm have been evaluated. However, no stand-alone diagnostic method
has emerged that more accurately identifies women at risk for preeclampsia, warranting
improvements in diagnosing Pre-E.
This sample collection study will obtain serum and urine samples from pregnant women who
present with clinical signs, symptoms, or conditions contributing to the suspicion of Pre-E.
Samples will be used to evaluate and validate the performance of an assay intended to aid in
assessing the risk of Pre-E.
Eligible subjects will provide written informed consent after which demographic and baseline
clinical data will be recorded.
Collection of whole blood and urine samples will be performed at one or more clinic visits
from pregnant women carrying a single fetus with no known fetal abnormalities.
Interim study visits will continue every 14 days [+/- 3 days] until the subject either: 1)
reaches 37 0/7 weeks' gestation, 2) develops Pre-E, 3) delivers, or 4) is lost to follow-up.
In addition, a group of pregnant women diagnosed with Pre-E will be enrolled as positive
control cases.
clinical data will be recorded.
Collection of whole blood and urine samples will be performed at one or more clinic visits
from pregnant women carrying a single fetus with no known fetal abnormalities.
Interim study visits will continue every 14 days [+/- 3 days] until the subject either: 1)
reaches 37 0/7 weeks' gestation, 2) develops Pre-E, 3) delivers, or 4) is lost to follow-up.
In addition, a group of pregnant women diagnosed with Pre-E will be enrolled as positive
control cases.
Eligibility criteria for the STUDY COHORT (CASES and NEGATIVE PRE-E
CONTROLS):
Inclusion Criteria:
- Subject is willing to provide informed consent and comply with study procedures
- 18 to 45 years of age
- Singleton fetus of 28 0/7 to 36 6/7 weeks' gestational age using the 2014 American
Congress of Obstetricians and Gynecologists (ACOG) Dating Criteria (pregnancies
starting as twins but complicated with either vanishing twin syndrome or fetal demise
of one twin before 14 weeks, are eligible for inclusion)
- Patient presenting with clinical suspicion of Pre-E based on either: New onset
elevated blood pressure in otherwise normotensive patient, worsening hypertension in a
patient with pre-existing hypertension, new onset proteinuria or worsening of
pre-existing proteinuria, or any other clinical finding requiring a workup to rule-out
Pre-E.
Exclusion Criteria:
- Pregnancy is non-viable or absence of fetal cardiac activity
- Diagnosis of Pre-E or anticipated delivery within 24 to 48 hours because of Pre-E with
severe features including: persistent severe hypertension (systolic ≥160 or diastolic
≥110; thrombocytopenia <100,000; liver enzymes 2x above upper normal limit or >70 with
severe persistent right upper quadrant (RUQ) or epigastric pain, new development of
renal insufficiency; pulmonary edema; new-onset persistent cerebral or visual
disturbances.
- Major fetal anomaly or chromosomal aneuploidy
- Current dialysis for kidney failure, including continuous ambulatory peritoneal
dialysis
Eligibility criteria for the POSITIVE CONTROL group:
Inclusion Criteria:
- Subject is willing to provide informed consent and comply with study procedures
- 18 to 45 years of age
- Singleton fetus of 28 0/7 to 36 6/7 weeks' gestational age using 2014 ACOG Dating
Criteria (pregnancies starting as twins but complicated with either vanishing twin
syndrome or fetal demise of one twin before 14 weeks, are eligible for inclusion)
- Patient diagnosed with Pre-E using 2013 ACOG guidelines
Exclusion Criteria:
- Pregnancy is non-viable or absence of cardiac activity
- Major fetal anomaly or chromosomal aneuploidy
- Current dialysis for kidney failure, including continuous ambulatory peritoneal
dialysis
We found this trial at
20
sites
Milwaukee, Wisconsin 53226
Phone: 414-805-6936
Click here to add this to my saved trials
Chapel Hill, North Carolina 27599
(919) 962-2211
Phone: 919-966-1601
University of North Carolina at Chapel Hill Carolina’s vibrant people and programs attest to the...
Click here to add this to my saved trials
Duke University Younger than most other prestigious U.S. research universities, Duke University consistently ranks among...
Click here to add this to my saved trials
2500 N State St
Jackson, Mississippi 39216
Jackson, Mississippi 39216
(601) 984-1000
Phone: 601-984-5377
University of Mississippi Medical Center The University of Mississippi Medical Center, located in Jackson, is...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
100 North Academy Avenue
Danville, Pennsylvania 17822
Danville, Pennsylvania 17822
570-271-6211
Phone: 570-214-6182
Geisinger Medical Center Since 1915, Geisinger Medical Center has been known as the region’s resource...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
1100 N. Lindsay
Oklahoma City, Oklahoma 73104
Oklahoma City, Oklahoma 73104
(405) 271-4000
Phone: 405-271-8001
University of Oklahoma The OU Health Sciences Center is composed of seven health-related colleges located...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials